Show All Hide All

Karen Akinsanya , Ph.D

Karen Akinsanya is the Executive Vice President, Chief Biomedical Scientist, and Head of Discovery R&D at Schrödinger. Karen has more than 25 years of experience in pharmaceutical R&D, clinical pharmacology, partnerships and licensing, having held numerous leadership positions at Merck & Co. Inc and at Ferring Pharmaceuticals. She led the discovery of a family of dipeptidyl peptidases related to DPPIV and pre-clinical characterization of FIRMAGON®, now FDA-approved for prostate cancer, while at Ferring. Karen went on to lead a cardiovascular therapeutic area team and the pre-POC licensing team, which brought >30 pipeline and new technology opportunities, at Merck before coming to Schrödinger.

Thomas Conrads , Ph.D

Thomas Conrads is a protein biochemist and serves as the Director of Women’s Health Research in the Inova Health System and the Chief Scientific Officer of the Department of Defense Gynecologic Cancer Center of Excellence. His career is focused on developing and applying cutting-edge applications and workflows in proteomics for cohort-scale analysis of clinically derived specimens, such as tissues, proximal fluids, and serum/plasma. The overarching goal of his efforts are toward identifying and validating protein biomarkers and surrogates for enhanced cancer patient management through improved early detection, patient stratification, and monitoring for therapeutic efficacy, outcome and recurrence.

Steve Gygi

Dr. Steve Gygi received his Ph.D. from the University of Utah in the area of pharmacology and toxicology. He joined the faculty at Harvard Medical School in 2000. He is currently a Professor in the Department of Cell Biology. Dr. Gygi is a technologist who uses mass spectrometry to answer fundamental questions in both normal and abnormal biology. He specializes in instrumentation advances for global cellular protein measurements.

William C. Hahn

Dr. William Hahn is a medical oncologist and Professor in the Department of Medical Oncology at the Dana-Farber Cancer Institute. Also at Dana-Faber, he co-directs the Center for Cancer Genome Discovery and serves as the Chief of the Division of Molecular and Cellular Oncology as well as Chair of the Executive Committee for Research. He is an Institute Member of the Broad Institute of MIT and Harvard. Dr. Hahn has made numerous seminal discoveries that have informed our current molecular understanding of cancer and which have defined new conceptual paradigms and formed the foundation of new translational studies.

C. Martin Harris , MD

Dr. Harris is currently Associate Vice President of the Health Enterprise and Chief Business Officer at the Dell Medical School at The University of Texas at Austin. Previously, he was CIO and Chairman of the Information Technology Division, as well as a Staff Physician at The Cleveland Clinic Foundation, Department of General Internal Medicine. He also served as a Staff Physician for the Cleveland Clinic Hospital. He is currently a member of Thermo Fisher Scientific’s Board of Directors and is also a director of Invacare Corporation, HealthStream Inc. and Colgate-Palmolive Company

Tyler Jacks

Dr. Tyler Jacks is the Director of MIT’s Koch Institute for Integrative Cancer Research and the David H. Koch Professor of Biology at MIT. He has pioneered the use of gene-targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, brain and ovary. His lab has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment. Dr. Jacks is also a member of Thermo Fisher Scientific’s Board of Directors.

David Sabatini

Dr. David Sabatini is a Member of the Whitehead Institute for Biomedical Research, and he is Senior Associate Member at the Broad Institute, Member of the Koch Institute for Integrative Cancer Research, and a Professor of Biology, all with the Massachusetts Institute of Technology (MIT). He is also a Howard Hughes Medical Institute Investigator. David and his lab at the Whitehead Institute study the basic mechanisms that regulate growth, the processes whereby cells and organisms accumulate mass and increase in size, as well as the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis.

Laura Sepp-Lorenzino

Dr. Sepp-Lorenzino joined Vertex in 2017 as VP, Head Nucleic Acid Therapies. From 2014 to 2017, she was VP, Entrepreneur-in-Residence at Alnylam, a leader in the development of RNAi Therapeutics. At Alnylam, she was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed Extra Hepatic siRNA Delivery internally, and via a number of collaborations, and was active in licensing and partnering. Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point, and having been an Assistant Lab Member and Assistant Attending Molecular Biologist at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.

Cynthia Wolberger

Dr. Wolberger is a structural biologist who is on the faculty of the Johns Hopkins University School of Medicine, where she is a Professor of Biophysics and Biophysical Chemistry. Dr. Wolberger has done pioneering work on the mechanisms underlying combinatorial regulation of transcription and on ubiquitin signaling. Her current research is focused on the mechanisms by which ubiquitin plays a signaling role in transcription and in the DNA damage response.

NYSE: TMO (Common Stock)

Investor Relations Kit

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

The world leader in serving science